Effects of multistrain probiotic supplementation on hepatic function and anthropometric parameters in patients with metabolic dysfunction-associated steatotic liver disease: a double-blind, randomized controlled trial.
NutritionJun 11, 2026 (epub)
Clinical ResearchGastroenterology
Małgorzata Moszak, Mariusz Kaczmarczyk, Matylda Kręgielska-Narożna et al.
✦ AI-curated · Sources linked
In 30 seconds
This double-blind, randomized controlled trial evaluated the effects of multistrain probiotic supplementation on hepatic function in 64 patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that probiotic supplementation significantly reduced the Fibrosis-4 index (FIB-4) by -0.05 compared to a 0.10 increase in the placebo group (P = 0.002), indicating potential benefits for liver function.
Key findings
- Probiotic group showed a significant reduction in FIB-4 (-0.05 vs. 0.10; P = 0.002).
- Aspartate aminotransferase levels decreased significantly in the probiotic group (-2.87 vs. 1.87 U/L; P < 0.001).
- APRI scores improved in the probiotic group (-0.03 vs. 0.02; P = 0.001).
- No significant changes were observed in anthropometric parameters or metabolic profiles.
Why it matters
The findings suggest that multistrain probiotics may offer a novel adjunctive approach to improve liver function in patients with MASLD, a condition with rising prevalence and limited treatment options.